Cancer Immunology, Immunotherapy Issues Research Articles in July 2024
June 18, 2024
June 18, 2024
BASEL, Switzerland, June 18 -- Cancer Immunology, Immunotherapy, a peer-reviewed journal that says it advances in the field of tumor immunology, published research articles on the following topics in its July 2024 edition (Vol. 73, Issue 7):
* The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients
* The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR . . .
* The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients
* The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR . . .